Development of a new drug for the treatment of Autism caused by Fragile X Syndrome
Lead Participant:
SENTINEL ONCOLOGY LIMITED
Abstract
Fragile X Syndrome is the single largest cause of genetically inherited disability amongst diseases
categorised within the autism spectrum disorders.
This proposal will aim to develop a new treatment for Fragile X syndrome, called SOL101, which will
treat the underlying cause of the disease rather than the symptoms. SOL101 has already demonstrated
proof of concept in pre-clinical disease models and the proposal will develop it to the start of clinical
trials.
As well as the healthcare benefits to the patiens, in terms of alleviation of symptoms, both neurological
and physical, the cost savings in terms of reduced needs for ongoing care and education assistance will
be considerable.
Finance summary table
categorised within the autism spectrum disorders.
This proposal will aim to develop a new treatment for Fragile X syndrome, called SOL101, which will
treat the underlying cause of the disease rather than the symptoms. SOL101 has already demonstrated
proof of concept in pre-clinical disease models and the proposal will develop it to the start of clinical
trials.
As well as the healthcare benefits to the patiens, in terms of alleviation of symptoms, both neurological
and physical, the cost savings in terms of reduced needs for ongoing care and education assistance will
be considerable.
Finance summary table
Lead Participant | Project Cost | Grant Offer |
---|---|---|
SENTINEL ONCOLOGY LIMITED | £1,609,388 | £ 965,633 |
  | ||
Participant |
||
INNOVATE UK |
People |
ORCID iD |
Stuart Travers (Project Manager) |